ASCO 2020 Breast/Gyn

CME

Key Studies in Breast and Gynecologic Cancers: Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 09, 2020

Expiration: September 08, 2021

Sara Hurvitz
Sara Hurvitz, MD

Activity

Progress
1
Course Completed

In this activity, Sara Hurvitz, MD, FACP, and Bradley J. Monk, MD, FACS, FACOG, review key breast and gynecologic cancer studies presented at the 2020 ASCO Virtual Scientific Meeting, focusing on new data.

Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets, each focused on the specific study or topic of interest. These slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing clinician, how many patients with breast or gynecologic cancers do you provide care for in a typical month?

Based on data from the phase III KEYNOTE-355 trial evaluating pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment for metastatic triple-negative breast cancer (TNBC) presented at ASCO 2020, which of the following patient subgroups based on PD-L1 expression level demonstrated improved PFS with the addition of pembrolizumab?

Which of the following would you tell a patient with PIK3CA-mutated, hormone receptor–positive, HER2-negative metastatic breast cancer and progression on her most recent therapy of a CDK4/6 inhibitor plus an aromatase inhibitor (AI) based on recently reported findings from the phase II BYLieve trial of alpelisib plus fulvestrant?

Which of the following outcomes was reported from the phase II AVANOVA2 trial with niraparib plus bevacizumab compared with niraparib alone for patients with platinum-sensitive recurrent ovarian cancer?